Information and Downloads
Here are downloadable resources for both healthcare professionals and patients
CLL=chronic lymphocytic leukaemia; 2L+=second line + later lines of therapy; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; BR=bendamustine + rituximab; VEN+R=VENCLYXTO® + rituximab.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA. Website: www.hpra.ie.
I want to find out more about VENCLYXTO®
I want to receive more information about VENCLYXTO®
Reference: 1. VENCLYXTO® Summary of Product Characteristics, available at www.medicines.ie
IE-VNCCLL-220023 | Date of preparation: March 2022